Interpace Biosciences, Inc.
IDXG
$0.65
-$0.35-35.00%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 12.32M | 12.30M | 12.04M | 10.27M | 10.11M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 12.32M | 12.30M | 12.04M | 10.27M | 10.11M |
| Cost of Revenue | 3.40M | 4.79M | 4.61M | 4.20M | 2.82M |
| Gross Profit | 8.92M | 7.51M | 7.43M | 6.07M | 7.29M |
| SG&A Expenses | 5.65M | 5.40M | 5.03M | 5.06M | 4.64M |
| Depreciation & Amortization | -- | -- | -- | -- | 27.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.24M | 10.39M | 9.79M | 9.40M | 7.63M |
| Operating Income | 3.07M | 1.91M | 2.26M | 874.00K | 2.47M |
| Income Before Tax | 2.87M | 1.37M | 2.14M | 576.00K | 1.97M |
| Income Tax Expenses | -8.00K | 4.00K | 4.00K | 4.00K | 5.00K |
| Earnings from Continuing Operations | 2.88M | 1.36M | 2.14M | 572.00K | 1.97M |
| Earnings from Discontinued Operations | 16.00K | -82.00K | -74.00K | -104.00K | 75.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2.89M | 1.28M | 2.06M | 468.00K | 2.04M |
| EBIT | 3.07M | 1.91M | 2.26M | 874.00K | 2.47M |
| EBITDA | 3.17M | 1.99M | 2.32M | 926.00K | 2.54M |
| EPS Basic | 0.55 | 0.29 | 0.47 | 0.11 | 0.47 |
| Normalized Basic EPS | 0.41 | 0.19 | 0.31 | 0.08 | 0.29 |
| EPS Diluted | 0.05 | 0.29 | 0.47 | 0.11 | 0.47 |
| Normalized Diluted EPS | 0.04 | 0.19 | 0.30 | 0.08 | 0.29 |
| Average Basic Shares Outstanding | 4.41M | 4.39M | 4.38M | 4.37M | 4.33M |
| Average Diluted Shares Outstanding | 49.72M | 4.42M | 4.40M | 4.38M | 4.34M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |